Diagnostic markers for glioblastoma
C.S. Jung1, A.W. Unterberg1 and C. Hartmann2
1Department of Neurosurgery and 2Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg and Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Germany.
Offprint requests to: Dr. Carla S. Jung, Department of Neurosurgery, University of Heidelberg, Im Neuenheimer Feld 400, 69121 Heidelberg, Germany. e-mail: email@example.com
Summary. Glioblastoma (GBM) is the most malignant form of cerebral gliomas, and despite distinct progress in surgical resection, radiation and chemotherapy, the prognosis of patients with GBM is still very poor. In the past decades knowledge of genomics and proteomics and of diagnostic, prognostic, predictive and pharmakodynamic markers measured in cerebrospinal-fluid (CSF), serum, or tumor tissue biomarkers has improved. This review briefly compiles our concepts on diagnostic markers for GBM, focusing on the latest developments. Histol Histopathol 26, 1327-1341 (2011)
Key words: Glioblastoma, Biomarker, Serum, Cerebrospinal fluid, Histopathology